Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Martin-Liberal

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 20, 2013
Systemic chemotherapy for inoperable, locally advanced, recurrent or metastatic uterine leiomyosarcomaJ Martin-Liberal, C Benson
European Journal of Cancer (Oxford, England : 1990)|June 8, 2017
Clinical research in small genomically stratified patient populationsJ Martin-Liberal, J Rodon
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2019
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejectionJ Ros, I Matos, J Martin-Liberal
Case Reports in Medicine|August 9, 2014
Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal SarcomaJ Martin-Liberal, C Benson, C Messiou, et al.
British Journal of Cancer|January 23, 2016
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanomaS Diem, B Kasenda, L Spain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?M Ochoa de Olza, M Oliva, C Hierro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?M O Ochoa de Olza, M Oliva, C Hierro, et al.
Biochimica Et Biophysica Acta|December 3, 2014
Targeting protein kinase C in sarcomaJ Martin-Liberal, A J Cameron, J Claus, et al.
British Journal of Cancer|July 9, 2014
Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumoursJ Martin-Liberal, M Gil-Martín, M Sáinz-Jaspeado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2026
Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and PitfallsO Mirallas, G Pretelli, M Balsa, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 20, 2013
Systemic chemotherapy for inoperable, locally advanced, recurrent or metastatic uterine leiomyosarcomaJ Martin-Liberal, C Benson
European Journal of Cancer (Oxford, England : 1990)|June 8, 2017
Clinical research in small genomically stratified patient populationsJ Martin-Liberal, J Rodon
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2019
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejectionJ Ros, I Matos, J Martin-Liberal
Case Reports in Medicine|August 9, 2014
Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal SarcomaJ Martin-Liberal, C Benson, C Messiou, et al.
British Journal of Cancer|January 23, 2016
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanomaS Diem, B Kasenda, L Spain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?M Ochoa de Olza, M Oliva, C Hierro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2019
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?M O Ochoa de Olza, M Oliva, C Hierro, et al.
Biochimica Et Biophysica Acta|December 3, 2014
Targeting protein kinase C in sarcomaJ Martin-Liberal, A J Cameron, J Claus, et al.
British Journal of Cancer|July 9, 2014
Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumoursJ Martin-Liberal, M Gil-Martín, M Sáinz-Jaspeado, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2026
Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and PitfallsO Mirallas, G Pretelli, M Balsa, et al.
Pageof 2